van der Leun Anne M, Traets Joleen J H, Vos Joris L, Elbers Joris B W, Patiwael Sanne, Qiao Xiaohang, Machuca-Ostos Mercedes, Thommen Daniela S, Haanen John B A G, Schumacher Ton N M, Zuur Charlotte L
Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Cancer Discov. 2023 Oct 5;13(10):2212-2227. doi: 10.1158/2159-8290.CD-22-0851.
To dissect the effect of neoadjuvant PD-1 and CTLA4 blockade on intratumoral T cells in treatment-naive head and neck squamous cell carcinoma, we analyzed primary tumor immune infiltrates from responding and nonresponding patients. At baseline, a higher ratio between active (4-1BB/OX40+) and inactive regulatory CD4+ T cells was associated with immunotherapy response. Furthermore, upon therapy, this active regulatory T-cell (Treg) population showed a profound decrease in responding patients. In an analogous process, intratumoral dysfunctional CD8+ T cells displayed decreased expression of activity and dysfunction-related genes in responding patients, whereas in clinical nonresponders, natural killer cells showed an increased cytotoxic profile early upon treatment. These data reveal immunologic changes in response to dual PD-1/CTLA4 blockade, including a parallel remodeling of presumed tumor-reactive Treg and CD8+ T-cell compartments in responding patients, and indicate that the presence of activated Tregs at baseline may be associated with response.
In head and neck squamous cell carcinoma, neoadjuvant PD-1/CTLA4 blockade has shown substantial response rates (20%-35%). As recognition of tumor antigens by T cells appears to be a critical driver of therapy response, a better understanding of alterations in T-cell state that are associated with response and resistance is of importance. This article is featured in Selected Articles from This Issue, p. 2109.
为剖析新辅助PD-1和CTLA4阻断对未经治疗的头颈部鳞状细胞癌肿瘤内T细胞的影响,我们分析了有反应和无反应患者的原发性肿瘤免疫浸润情况。在基线时,活跃的(4-1BB/OX40+)与不活跃的调节性CD4+ T细胞之间的比例较高与免疫治疗反应相关。此外,在治疗后,这种活跃的调节性T细胞(Treg)群体在有反应的患者中显著减少。在类似的过程中,肿瘤内功能失调的CD8+ T细胞在有反应的患者中活性和功能相关基因的表达降低,而在临床无反应者中,自然杀伤细胞在治疗早期细胞毒性特征增加。这些数据揭示了对双重PD-1/CTLA4阻断的免疫反应变化,包括在有反应的患者中假定的肿瘤反应性Treg和CD8+ T细胞区室的平行重塑,并表明基线时活化Tregs的存在可能与反应相关。
在头颈部鳞状细胞癌中,新辅助PD-1/CTLA4阻断已显示出相当高的反应率(20%-35%)。由于T细胞对肿瘤抗原的识别似乎是治疗反应的关键驱动因素,更好地了解与反应和耐药相关的T细胞状态改变具有重要意义。本文是本期精选文章之一,第2109页。